Satellos Bioscience Inc.
MSCLF
$0.4284
$0.01934.72%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 21.07% | 3.09% | 49.94% | 17.37% | 188.32% |
| Gross Profit | -21.07% | -3.09% | -49.94% | -17.37% | -188.32% |
| SG&A Expenses | 45.70% | 12.49% | -16.72% | 0.86% | 19.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.12% | 5.73% | 21.53% | 10.92% | 114.74% |
| Operating Income | -30.12% | -5.73% | -21.53% | -10.92% | -114.74% |
| Income Before Tax | -26.04% | -18.48% | 9.19% | -148.96% | -44.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.76% | -19.71% | 9.19% | -148.96% | -44.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.76% | -19.71% | 9.19% | -148.96% | -44.42% |
| EBIT | -30.12% | -5.73% | -21.53% | -10.92% | -114.74% |
| EBITDA | -30.18% | -5.75% | -21.39% | -10.93% | -114.72% |
| EPS Basic | 16.33% | 18.68% | 15.02% | -148.73% | 0.00% |
| Normalized Basic EPS | 16.73% | 19.37% | 15.04% | -58.46% | 0.00% |
| EPS Diluted | 16.33% | 18.68% | 15.02% | -148.73% | 0.00% |
| Normalized Diluted EPS | 16.73% | 19.37% | 15.04% | -58.46% | 0.00% |
| Average Basic Shares Outstanding | 51.80% | 47.02% | 6.83% | 0.21% | 44.29% |
| Average Diluted Shares Outstanding | 51.80% | 47.02% | 6.83% | 0.21% | 44.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |